Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Generated: April 24, 2018

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 020762

« Back to Dashboard

NDA 020762 describes NASONEX, which is a drug marketed by Merck Sharp Dohme and is included in one NDA. It is available from two suppliers. There is one patent protecting this drug and one Paragraph IV challenge. Additional details are available on the NASONEX profile page.

The generic ingredient in NASONEX is mometasone furoate. There are twenty-nine drug master file entries for this compound. Sixteen suppliers are listed for this compound. Additional details are available on the mometasone furoate profile page.

Summary for 020762

Tradename:	NASONEX
Applicant:	Merck Sharp Dohme
Ingredient:	mometasone furoate
Patents:	1
Therapeutic Class:	Hormonal Agents, Stimulant/Replacement/Modifying (Adrenal)
Formulation / Manufacturing:	see details

Pharmacology for NDA: 020762

Mechanism of Action	Corticosteroid Hormone Receptor Agonists

Medical Subject Heading (MeSH) Categories for 020762

Anti-Allergic Agents
Anti-Inflammatory Agents
Dermatologic Agents

Suppliers and Packaging for NDA: 020762

Tradename	Generic Name	Dosage	NDA	Application Type	Supplier	National Drug Code	Package Code	Package
NASONEX	mometasone furoate	SPRAY, METERED;NASAL	020762	NDA	Merck Sharp & Dohme Corp.	0085-1288	N	0085-1288-01
NASONEX	mometasone furoate	SPRAY, METERED;NASAL	020762	NDA	Merck Sharp & Dohme Corp.	0085-1288	N	0085-1288-03

Profile for product number 001

Active Rx/OTC/Discontinued:	RX	Dosage:	SPRAY, METERED;NASAL			Strength	EQ 0.05MG BASE/SPRAY
Approval Date:	Oct 1, 1997	TE:	AB	RLD:	Yes
Patent:	➤ Sign Up	Patent Expiration:	Apr 3, 2018	Product Flag?		Substance Flag?		Delist Request?

Expired US Patents for NDA 020762

This preview shows a limited data set. Subscribe for full access, or try a Free Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Merck Sharp Dohme	NASONEX	mometasone furoate	SPRAY, METERED;NASAL	020762-001	Oct 1, 1997	➤ Sign Up	➤ Sign Up
Merck Sharp Dohme	NASONEX	mometasone furoate	SPRAY, METERED;NASAL	020762-001	Oct 1, 1997	➤ Sign Up	➤ Sign Up
Merck Sharp Dohme	NASONEX	mometasone furoate	SPRAY, METERED;NASAL	020762-001	Oct 1, 1997	➤ Sign Up	➤ Sign Up
Merck Sharp Dohme	NASONEX	mometasone furoate	SPRAY, METERED;NASAL	020762-001	Oct 1, 1997	➤ Sign Up	➤ Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration

Complete Access Available with Subscription

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.